Searchable abstracts of presentations at key conferences in endocrinology

ea0011p195 | Clinical practise and governance | ECE2006

Long-term outcome in men with microprolactinoma

Rea R , Jeffcoate W

Introduction: It is accepted that hyperprolactinaemia associated with microprolactinoma may prove self-limiting in 25–30% women, and there is some suggestion from series of mixed gender that the same may be true in men.Methods: We have therefore reviewed the outcome in all men with microprolactinomas managed at the Department of Diabetes and Endocrinology, City Hospital, Nottingham, between 1994 and 2002. All had sustained and previously untreated h...

ea0021p18 | Bone | SFEBES2009

Management of primary hyperparathyroidism: are we following the guidelines?

Mohammed Abdul Rafi , Cheung Joyce , Rea Rustam

In 2008, we presented data showing that combining sonography and scintigraphy investigations resulted in the correct identification of a parathyroid adenoma in 97% (28/29) patients undergoing parathyroid surgery for primary hyperparathyroidism (PHPT). Further to this audit we compared the treatment of PHPT against the standards set by NIH in 2008. All patients who had Setamibi +/ ultrasound scan over 18 month (July 2006 until December 2007) for biochemically confirmed PHPT wer...

ea0063p1016 | Interdisciplinary Endocrinology 2 | ECE2019

Differential impact of body mass index on bone and breast density in post-menopausal women and potential implications for the risk of breast cancer

Filipponi Silvia , Iacobelli Daniela , Di Cesare Ernesto , Penniello Luciano , Rea Silvio , Jaffrain-Rea Marie-Lise

Introduction: Women with a high breast density have an increased risk of breast cancer, which prevalence increases after menopause in obese subjects. Breast density can be calculated on mammograms as the proportion of dense tissue (percent mammographic density-PMD). Several factors may influence the PMD, including age, menopausal status, body mass index (BMI), and bone mineral density (BMD) taken as an index of overall estrogen exposure. However, conflicting data have been rep...

ea0065p20 | Adrenal and Cardiovascular | SFEBES2019

Can short Synacthen tests (SST) be rationalised by establishing a lower baseline cortisol level which will predict SST outcome?

Lange Maria , Rea Kathy , Geevarghese Cheriyan , Kotonya Christine

Aim: Shortage of tetracosactide in the UK has put pressure on clinicians to reduce the number of SST’s ordered. Our aim was to establish if a lower baseline cortisol level from the currently accepted cut-off could predict a positive SST outcome. This would aid our Endocrine Department in rationalising use of tetracosactide.Methods: A retrospective observational study of indications and results of SST’s performed in non-critically ill general me...

ea0037ep1094 | Endocrine tumours | ECE2015

Plasma chromogranin A and chromogranin B concentrations in untreated patients with mid gut carcinoid and their biochemical response to octreotide

Armstrong Lee , Rea Teresa , Johnston Brian , McCance David

We measured chromogranin A (CgA) and chromogranin B (CgB) in 36 patients, recently confirmed to have a midgut carcinoid tumour (MGC), prior to the commencement of octreotide treatment. Blood samples were taken before and after a bolus injection of 50 μg octreotide. There were 21 males, 15 females, age range 28–76 median 61 years.Basal CgA, expressed as times the upper limit of normal (ULN) ranged from 333.3 to 0.5 ULN. Basal CgB ranged from 33....

ea0035p929 | Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

Malignancies in patients with pituitary adenomas

Filipponi Silvia , Cantore Giampaolo , Jaffrain-Rea Marie-Lise

Abstract: Generously supported by IPSEN)-->Pituitary adenomas (PA) may occur in association with malignancies. Although an increased risk of cancer has been reported in acromegalics, this has been poorly studied in patients with other phenotypes. We wished to evaluate the prevalence of recognized malignancies in PA.Material and Methods: A series of 422 consecutive PA patients followed at the Neuromed Institute ...

ea0031p30 | Bone | SFEBES2013

Cinacalcet treatment for hypercalcaemia in primary hyperparathyroidism

Seetho Ian , Qazi Shah , Amin Pesh , Rea Rustam

Introduction: Cinacalcet acts at the calcium-sensing receptors on parathyroid cells to increase the sensitivity to circulating calcium concentrations. Studies have shown that this treatment is an effective means of managing hypercalcaemia in primary hyperparathyroidism.Aims: The aim of this study was to determine the outcomes of patients who had received cinacalcet for at least 3 months for primary hyperparathyroidism.Methods: We i...

ea0022p663 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Sellar lesions in Ollier disease: case report and a review of the literature

Jaffrain-Rea Marie-Lise , Giangaspero Felice , Esposito Vincenzo , Cantore Giampaolo

Ollier disease (OD) is a rare disease, with multiple enchondromas localized in the metaphysis of long bones, hands and feet, developing in the first decade of life, with potential malignant transformation into chondrosarcomas. OD is usually sporadic and probably caused by post-zygotic genetic alterations leading to mosaicism. A PTH/PTHrP receptor type 1 (PTHR1) gene mutation is present in some cases.Case report: A 21-years old male patient was referred t...

ea0019p34 | Clinical practice/governance and case reports | SFEBES2009

Primary hyperparathyroidism: dual localisation to improve cure rate

Wilmot E , Cozens N , Birchall J , Lingam K , Rea R

Aims: Primary hyperparathyroidism is a common endocrine disorder. A preoperative approach that combines ultra-sonography and scintigraphy has been shown to predict the presence of adenomas more accurately than either technique alone. We aimed to investigate our local success rates using dual localisation for parathyroid adenomas.Methods: Endocrine patients who had a parathyroidectomy between July 2006 and January 2008 were identified. Hospital notes were...

ea0019p368 | Thyroid | SFEBES2009

Efficacy and complications of radioiodine therapy in benign thyroid disease

Seetho I , Ibbett D , Birchall J , Rea R

The RCP clinical guideline on Radioiodine in the management of benign thyroid disease was published in 2007. An audit was undertaken in patients receiving this treatment between April 2006 and April 2007. The audit was performed to assess compliance with the guidelines and provide patients receiving radioiodine data regarding the efficacy of the treatment and its complications.Sixty-two patients received radioiodine and 59 patients entered into the audit...